Overview

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Drotrecogin alfa activated
Protein C